115 related articles for article (PubMed ID: 30610829)
1. Role of mTOR signaling pathway proteins and proteins influencing mTOR pathway in resistance to radiotherapy in prostate cancer.
Benderli Cihan Y
J BUON; 2018; 23(6):1931-1932. PubMed ID: 30610829
[No Abstract] [Full Text] [Related]
2. Akt-regulated pathways in prostate cancer.
Majumder PK; Sellers WR
Oncogene; 2005 Nov; 24(50):7465-74. PubMed ID: 16288293
[TBL] [Abstract][Full Text] [Related]
3. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
4. The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.
Riquelme I; Tapia O; Espinoza JA; Leal P; Buchegger K; Sandoval A; Bizama C; Araya JC; Peek RM; Roa JC
Pathol Oncol Res; 2016 Oct; 22(4):797-805. PubMed ID: 27156070
[TBL] [Abstract][Full Text] [Related]
5. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
Kim JG; Chae YS; Sohn SK; Kang BW; Moon JH; Lee SJ; Jeon SW; Park JS; Park JY; Choi GS
Oncology; 2010; 79(3-4):278-82. PubMed ID: 21412012
[TBL] [Abstract][Full Text] [Related]
7. miR-410-3p promotes prostate cancer progression via regulating PTEN/AKT/mTOR signaling pathway.
Zhang Y; Zhang D; Lv J; Wang S; Zhang Q
Biochem Biophys Res Commun; 2018 Sep; 503(4):2459-2465. PubMed ID: 29969630
[TBL] [Abstract][Full Text] [Related]
8. [Activation of AKT of signaling pathway and the level of mTOR substrates in tumor of patients with kidney cancer, connection with prevalence of malignancy].
Spirina LV; Usynin EA; Kondakova IV; Yurmazov ZA; Slonimskaya EM; Kolegova ES
Vopr Onkol; 2016; 62(3):490-4. PubMed ID: 30463106
[TBL] [Abstract][Full Text] [Related]
9. [Role of PTEN protein in multidrug resistance of prostate cancer cells].
Sherbakova EA; Stromskaia TP; Rybalkina EIu; Kalita OV; Stavrovskaia AA
Mol Biol (Mosk); 2008; 42(3):487-93. PubMed ID: 18702307
[TBL] [Abstract][Full Text] [Related]
10. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
11. STX3 represses the stability of the tumor suppressor PTEN to activate the PI3K-Akt-mTOR signaling and promotes the growth of breast cancer cells.
Nan H; Han L; Ma J; Yang C; Su R; He J
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1684-1692. PubMed ID: 29408595
[TBL] [Abstract][Full Text] [Related]
12. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
[TBL] [Abstract][Full Text] [Related]
13. miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway.
Wang P; Guan Q; Zhou D; Yu Z; Song Y; Qiu W
DNA Cell Biol; 2018 Jan; 37(1):38-45. PubMed ID: 29185784
[TBL] [Abstract][Full Text] [Related]
14. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
[TBL] [Abstract][Full Text] [Related]
15. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
16. miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.
Liu J; Xing Y; Rong L
Oncol Rep; 2018 Apr; 39(4):1631-1639. PubMed ID: 29484437
[TBL] [Abstract][Full Text] [Related]
17. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
[TBL] [Abstract][Full Text] [Related]
18. Simulated Microgravity Influences VEGF, MAPK, and PAM Signaling in Prostate Cancer Cells.
Hybel TE; Dietrichs D; Sahana J; Corydon TJ; Nassef MZ; Wehland M; Krüger M; Magnusson NE; Bauer J; Utpatel K; Infanger M; Grimm D; Kopp S
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070055
[TBL] [Abstract][Full Text] [Related]
19. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
20. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
